Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate

MJ Marks and AC Collins

The binding of [3H]nicotine to mouse brain has been measured and subsequently compared with the binding of [125I]alpha-bungarotoxin (alpha-BTX) and L-[3H]quinuclidinyl benzilate (QNB). The binding of nicotine was saturable, reversible, and stereospecific. The average KD and Bmax were 59 nM and 88 fmoles/mg of protein, respectively. Although the rates of association and dissociation of nicotine were temperature- dependent, the incubation temperature had no effect on either KD or Bmax. When measured at 20 degrees or 37 degrees, nicotine appeared to bind to a single class of binding sites, but a second, very low- affinity, binding site was observed at 4 degrees. Nicotine binding was unaffected by the addition of NaCl, KCl, CaCl2, or MgSO4 to the incubation medium. Nicotinic cholinergic agonists were potent inhibitors of nicotine binding; however, nicotinic antagonists were poor inhibitors. The regional distribution of binding was not uniform: midbrain and striatum contained the highest number of receptors, whereas cerebellum had the fewest. Differences in site densities, regional distribution, inhibitor potencies, and thermal denaturation indicated that nicotine binding was not the same as either QNB or alpha- BTX binding, and therefore that receptors for nicotine may represent a unique population of cholinergic receptors.

Volume 22, Issue 3, pp. 554-564, 11/01/1982
Copyright © 1982 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				W. R. Kem, V. M. Mahnir, L. Prokai, R. L. Papke, X. Cao, S. LeFrancois, K. Wildeboer, K. Prokai-Tatrai, J. Porter-Papke, and F. Soti Hydroxy Metabolites of the Alzheimer's Drug Candidate 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (GTS-21): Their Molecular Properties, Interactions with Brain Nicotinic Receptors, and Brain Penetration Mol. Pharmacol., January 1, 2004; 65(1): 56 - 67. [Abstract] [Full Text] [PDF]

				J. B. Eaton, J.-H. Peng, K. M. Schroeder, A. A. George, J. D. Fryer, C. Krishnan, L. Buhlman, Y.-P. Kuo, O. Steinlein, and R. J. Lukas Characterization of Human {alpha}4{beta}2-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed in Native Nicotinic Receptor-Null SH-EP1 Human Epithelial Cells Mol. Pharmacol., December 1, 2003; 64(6): 1283 - 1294. [Abstract] [Full Text] [PDF]

				V. Batra, A. A. Patkar, W. H. Berrettini, S. P. Weinstein, and F. T. Leone The Genetic Determinants of Smoking Chest, May 1, 2003; 123(5): 1730 - 1739. [Abstract] [Full Text] [PDF]

				M. Quik, Y. Polonskaya, J. M. Kulak, and J. M. McIntosh Vulnerability of 125I-{alpha}-Conotoxin MII Binding Sites to Nigrostriatal Damage in Monkey J. Neurosci., August 1, 2001; 21(15): 5494 - 5500. [Abstract] [Full Text] [PDF]

				C. P. Fenster, T. L. Whitworth, E. B. Sheffield, M. W. Quick, and R. A. J. Lester Upregulation of Surface alpha 4beta 2 Nicotinic Receptors Is Initiated by Receptor Desensitization after Chronic Exposure to Nicotine J. Neurosci., June 15, 1999; 19(12): 4804 - 4814. [Abstract] [Full Text] [PDF]

				M. I. Damaj, J. E. Slemmer, F. I. Carroll, and B. R. Martin Pharmacological Characterization of Nicotine's Interaction with Cocaine and Cocaine Analogs J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1229 - 1236. [Abstract] [Full Text]

				C. P. Fenster, M. L. Beckman, J. C. Parker, E. B. Sheffield, T. L. Whitworth, M. W. Quick, and R. A. J. Lester Regulation of alpha 4beta 2 Nicotinic Receptor Desensitization by Calcium and Protein Kinase C Mol. Pharmacol., March 1, 1999; 55(3): 432 - 443. [Abstract] [Full Text]

				Y. Lu, S. Grady, M. J. Marks, M. Picciotto, J.-P. Changeux, and A. C. Collins Pharmacological Characterization of Nicotinic Receptor-stimulated GABA Release From Mouse Brain Synaptosomes J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 648 - 657. [Abstract] [Full Text]

				M. J. Marks, K. W. Smith, and A. C. Collins Differential Agonist Inhibition Identifies Multiple Epibatidine Binding Sites in Mouse Brain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 377 - 386. [Abstract] [Full Text]

				J. A. Stitzel, J. M. Blanchette, and A. C. Collins Sensitivity to the Seizure-Inducing Effects of Nicotine is Associated with Strain-Specific Variants of the alpha 5 and alpha 7 Nicotinic Receptor Subunit Genes J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1104 - 1111. [Abstract] [Full Text]

				W. R. Kem, V. M. Mahnir, R. L. Papke, and C. J. Lingle Anabaseine Is a Potent Agonist on Muscle and Neuronal Alpha-Bungarotoxin-Sensitive Nicotinic Receptors J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 979 - 992. [Abstract] [Full Text]

				M. I. Dávila-García, J. L. Musachio, D. C. Perry, Y. Xiao, A. Horti, E. D. London, R. F. Dannals, and K. J. Kellar [125I]IPH, an Epibatidine Analog, Binds with High Affinity to Neuronal Nicotinic Cholinergic Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 445 - 451. [Abstract] [Full Text]